Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033

Inclusion criteria

• The patient shall sign the Informed Consent Form;
• Aged ≥ 18 years;
• Patients with definitely incidental SCLC confirmed by pathological results after radical resection of lung cancer;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• Life expectancy is at least 12 weeks;
• Good function of other major organs (liver, kidney, hematological system, etc.);
• Fertile female patients must undergo a pregnancy test within 7 days before the start of treatment with a negative result; and reliable contraceptive measures (such as intrauterine devices, contraceptives and condoms) should be used during the trial and within 30 days after its completion;
• Fertile male subjects must use condoms for contraception during the trial and within 30 days after its completion.

Exclusion criteria

• Patients with a malignancy other than SCLC within five years prior to the start of this trial;
• Participants with any unstable systemic disease (including uncontrolled hypertension, severe arrhythmia, etc.);
• With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;
• Participants who are allergic to the test drug or any auxiliary materials;
• Participants with active hepatitis B, hepatitis C or HIV;
• Participants with Interstitial lung disease currently;
• Pregnant or lactating women;
• Any malabsorption;
• Participants suffering from nervous system diseases or mental diseases that cannot cooperate;
• Other factors that researchers think it is not suitable for enrollment.